Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Corcept Therapeutics
Medical College of Wisconsin
Parabilis Medicines, Inc.
Genmab
Alliance Foundation Trials, LLC.
AstraZeneca
Whitehawk Therapeutics, Inc.
Qilu Pharmaceutical Co., Ltd.
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
University of Oklahoma
Centre Leon Berard
Merck Sharp & Dohme LLC
Yonsei University
Exelixis
Ohio State University Comprehensive Cancer Center
University of Oklahoma
University of Oklahoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Oklahoma
The Cleveland Clinic
Dana-Farber Cancer Institute
Catholic University of the Sacred Heart